News 4|1|04

home

pipeline

EC Mechanism

quarterly reports





Click here for animation

< news & articles >:

Cell>Point completes clinical pilot study on ^99mTc-EC-Annexin V ā€” 4|1|04

HOUSTON,Texas-April1,2004 -Cell>Point L.L.C. completes clinical pilot study on ^99mTc-EC-Annexin V at The University of Texas M.D. Anderson Cancer Center. The study evaluated the use of ^99m Tc-EC-Annexin V to assess tumor apoptosis (programmed cell death) in patients with primary breast cancer and to detect and image treatment related apoptosis in patients with primary breast cancer. The images produced in the study exceeded the companyĀ’s expectations. By using ^99mTc-EC-Annexin V, the oncologist will be able to detect cell death much more quickly than current practice.

© copyright 2001-2007|Cell>Point L.L.C | all rights reserved | maintained by Link2City.com

Terry Colip

Home | About Us | Management Team | Scientific Advisory Board | Corporate fact Sheet
EC Mechanism of Action | Video | R & D | Agents Pipeline | News | Articles | Patents | Corp Financials | Contact Us